10-Q: Viatris Reports Mixed Q3 Results Amidst Strategic Divestitures and Acquisitions

Viatris's Q3 2024 results show a decrease in revenue and earnings, influenced by strategic divestitures and new acquisitions.

Summary

• Viatris reported a decrease in total revenue to $3.75 billion for Q3 2024, down from $3.94 billion in Q3 2023.
• Net sales decreased by 5% year-over-year, primarily due to divestitures and unfavorable currency exchange rates.
• The company's gross profit decreased to $1.46 billion, with a gross margin of 39%, compared to $1.69 billion and 43% respectively in the prior year period.
• Operating expenses decreased slightly to $1.23 billion, with a notable decrease in SG&A expenses.
• Net earnings for the quarter were $94.8 million, a significant decrease from $331.6 million in the same period last year.
• Diluted earnings per share decreased to $0.08 from $0.27 year-over-year.
• For the nine months ended September 30, 2024, total revenues were $11.21 billion, a decrease from $11.59 billion in the prior year period.
• Net loss for the nine months was $117.7 million, compared to net earnings of $820.3 million in the prior year period.
• Diluted loss per share was $0.10, compared to diluted earnings per share of $0.68 in the prior year period.
• The company completed the acquisition of Idorsia's development programs for $350 million upfront, with potential future milestone payments.
• Viatris completed the divestiture of its OTC business, womens healthcare business, and API business in India during the quarter.

Sentiment

Score: 4

Explanation: The document presents mixed results with a clear negative trend in earnings and profitability, offset by strategic moves like divestitures and acquisitions. The sentiment is cautiously negative due to the financial underperformance, but there are some positive aspects related to future growth potential.

Positives

• New product sales contributed positively to revenue, particularly in Developed Markets.
• Constant currency net sales from the remaining business increased by approximately $109.4 million, or 3%, for the three months ended September 30, 2024 compared to the prior year period.
• The company completed strategic divestitures, which are expected to streamline operations.
• The acquisition of Idorsia's development programs expands the company's innovative asset portfolio.
• The company has access to $3.5 billion under the 2024 Revolving Facility which matures in September 2029.

Negatives

• Total revenue decreased by 5% year-over-year, primarily due to divestitures and unfavorable currency exchange rates.
• Net earnings decreased significantly to $94.8 million from $331.6 million year-over-year.
• Diluted earnings per share decreased to $0.08 from $0.27 year-over-year.
• The company recorded a goodwill impairment charge of $321 million related to its JANZ reporting unit.
• The company recorded a net loss on divestitures of approximately $107.4 million for the three months ended September 30, 2024.
• The company recorded a net loss on divestitures of approximately $295.8 million for the nine months ended September 30, 2024.

Risks

• The company faces risks related to the timely and successful completion of the Idorsia development programs.
• The company is subject to ongoing legal proceedings, including government inquiries and investigations, which could have a material impact.
• The company is subject to income taxes and tax audits in many jurisdictions, and the resolution of these matters may span multiple years.
• The company is exposed to foreign currency risk and interest rate risk, which could impact financial results.
• The company is subject to risks related to the global pharmaceutical industry, including competition, pricing pressures, and regulatory changes.

Future Outlook

The company expects to continue to evaluate potential acquisitions and divestitures as part of its future strategy and explore ways to create shareholder value. The company expects to make total benefit payments of approximately $114.4 million from pension and other postretirement benefit plans in 2024. The company anticipates making contributions to pension and other postretirement benefit plans of approximately $61.3 million in 2024. Capital expenditures for the 2024 calendar year are expected to be approximately $350 million to $450 million.

Management Comments

• Viatris executive management team is focused on ensuring that the Company is optimally structured and efficiently resourced to deliver sustainable value to patients, shareholders, customers and other key stakeholders.
• The Company has industry leading commercial, R&D, regulatory, manufacturing, legal and medical expertise complemented by a strong commitment to quality and an unparalleled geographic footprint to deliver high-quality medicines to patients in more than 165 countries and territories.

Industry Context

The global pharmaceutical industry is highly competitive and regulated, with factors such as generic competition, pricing pressures, and regulatory changes significantly impacting financial results. Viatris is navigating these challenges through strategic divestitures and acquisitions, focusing on complex products and innovative assets.

Comparison to Industry Standards

• Viatris's performance is being impacted by generic competition, similar to other companies in the industry, particularly in the U.S. market.
• The company's strategic divestitures and acquisitions are in line with industry trends of portfolio optimization and focusing on core competencies.
• The company's focus on complex products and innovative assets is a strategy employed by other pharmaceutical companies to drive growth and improve margins.
• The company's adjusted EBITDA margin of approximately 34% for the nine months ended September 30, 2024 is comparable to other large pharmaceutical companies, but is lower than some of the more specialized or innovative companies.
• The company's debt levels are significant, which is common in the pharmaceutical industry, but the company is actively managing its debt through repayments and refinancing.

Legal Proceedings

• The company is involved in various disputes, governmental and/or regulatory inquiries, investigations and proceedings, tax proceedings and litigation matters, both in the U.S. and abroad.
• The company is a defendant in lawsuits related to the pricing and/or marketing of the EpiPen Auto-Injector.
• The company is a defendant in lawsuits alleging anticompetitive conduct with respect to generic drugs.
• The company is a defendant in lawsuits related to sales, marketing and/or distribution practices with respect to prescription opioid products.
• The company is involved in patent litigation lawsuits involving the validity and/or infringement of patents.
• The company is involved in product liability lawsuits related to alleged personal injuries arising out of certain products.

Stakeholder Impact

• Shareholders are impacted by the decrease in earnings and diluted earnings per share.
• Employees are impacted by restructuring and divestiture activities.
• Customers are impacted by changes in product availability and pricing.
• Suppliers are impacted by changes in the company's supply chain.
• Creditors are impacted by the company's debt levels and repayment obligations.

Next Steps

• The company will continue to evaluate potential acquisitions and divestitures.
• The company will continue to develop and commercialize new products.
• The company will continue to manage its debt and liquidity.
• The company will continue to defend itself in ongoing legal proceedings.

Key Dates

Keywords

Viatris, financial results, quarterly report, divestitures, acquisitions, pharmaceuticals, revenue, earnings, EBITDA, debt, biosimilars, generics, brands, litigation, restructuring